BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Klein E, Nagy N, Rasul AE. EBV genome carrying B lymphocytes that express the nuclear protein EBNA-2 but not LMP-1: Type IIb latency. Oncoimmunology 2013;2:e23035. [PMID: 23526738 DOI: 10.4161/onci.23035] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Price AM, Luftig MA. To be or not IIb: a multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesis. PLoS Pathog 2015;11:e1004656. [PMID: 25790223 DOI: 10.1371/journal.ppat.1004656] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 8.7] [Reference Citation Analysis]
2 Almeida JFM, Campos AH, Marcello MA, Bufalo NE, Rossi CL, Amaral LHP, Marques AB, Cunha LL, Alvarenga CA, Tincani PC, Tincani AJ, Ward LS. Investigation on the association between thyroid tumorigeneses and herpesviruses. J Endocrinol Invest 2017;40:823-9. [PMID: 28276007 DOI: 10.1007/s40618-017-0609-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
3 McHugh D, Caduff N, Barros MHM, Rämer PC, Raykova A, Murer A, Landtwing V, Quast I, Styles CT, Spohn M, Fowotade A, Delecluse HJ, Papoudou-Bai A, Lee YM, Kim JM, Middeldorp J, Schulz TF, Cesarman E, Zbinden A, Capaul R, White RE, Allday MJ, Niedobitek G, Blackbourn DJ, Grundhoff A, Münz C. Persistent KSHV Infection Increases EBV-Associated Tumor Formation In Vivo via Enhanced EBV Lytic Gene Expression. Cell Host Microbe 2017;22:61-73.e7. [PMID: 28704654 DOI: 10.1016/j.chom.2017.06.009] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 17.3] [Reference Citation Analysis]
4 Frappier L. Epstein-Barr virus: Current questions and challenges. Tumour Virus Res 2021;12:200218. [PMID: 34052467 DOI: 10.1016/j.tvr.2021.200218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Grywalska E, Rolinski J. Epstein-Barr Virus–Associated Lymphomas. Seminars in Oncology 2015;42:291-303. [DOI: 10.1053/j.seminoncol.2014.12.030] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 11.1] [Reference Citation Analysis]
6 Agathangelidis A, Scarfò L, Barbaglio F, Apollonio B, Bertilaccio MT, Ranghetti P, Ponzoni M, Leone G, De Pascali V, Pecciarini L, Ghia P, Caligaris-Cappio F, Scielzo C. Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line. PLoS One 2015;10:e0130195. [PMID: 26110819 DOI: 10.1371/journal.pone.0130195] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
7 Dolcetti R, Dal Col J, Martorelli D, Carbone A, Klein E. Interplay among viral antigens, cellular pathways and tumor microenvironment in the pathogenesis of EBV-driven lymphomas. Seminars in Cancer Biology 2013;23:441-56. [DOI: 10.1016/j.semcancer.2013.07.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 4.9] [Reference Citation Analysis]
8 Niller HH, Banati F, Salamon D, Minarovits J. Epigenetic Alterations in Epstein-Barr Virus-Associated Diseases. In: Minarovits J, Niller HH, editors. Patho-Epigenetics of Infectious Disease. Cham: Springer International Publishing; 2016. pp. 39-69. [DOI: 10.1007/978-3-319-24738-0_3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
9 Stanfield BA, Luftig MA. Recent advances in understanding Epstein-Barr virus. F1000Res 2017;6:386. [PMID: 28408983 DOI: 10.12688/f1000research.10591.1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
10 Kozireva S, Rudevica Z, Baryshev M, Leonciks A, Kashuba E, Kholodnyuk I. Upregulation of the Chemokine Receptor CCR2B in Epstein‒Barr Virus-Positive Burkitt Lymphoma Cell Lines with the Latency III Program. Viruses 2018;10:E239. [PMID: 29751565 DOI: 10.3390/v10050239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Rasul E, Salamon D, Nagy N, Leveau B, Banati F, Szenthe K, Koroknai A, Minarovits J, Klein G, Klein E. The MEC1 and MEC2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia. PLoS One 2014;9:e106008. [PMID: 25162594 DOI: 10.1371/journal.pone.0106008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bayda N, Tilloy V, Chaunavel A, Bahri R, Halabi MA, Feuillard J, Jaccard A, Ranger-Rogez S. Comprehensive Epstein-Barr Virus Transcriptome by RNA-Sequencing in Angioimmunoblastic T Cell Lymphoma (AITL) and Other Lymphomas. Cancers (Basel) 2021;13:610. [PMID: 33557089 DOI: 10.3390/cancers13040610] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Niller HH, Szenthe K, Minarovits J. Epstein-Barr virus-host cell interactions: an epigenetic dialog? Front Genet 2014;5:367. [PMID: 25400657 DOI: 10.3389/fgene.2014.00367] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
14 Münz C. Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. Nat Rev Microbiol 2019;17:691-700. [PMID: 31477887 DOI: 10.1038/s41579-019-0249-7] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 28.0] [Reference Citation Analysis]
15 Blanco R, Carrillo-Beltrán D, Osorio JC, Calaf GM, Aguayo F. Role of Epstein-Barr Virus and Human Papillomavirus Coinfection in Cervical Cancer: Epidemiology, Mechanisms and Perspectives. Pathogens 2020;9:E685. [PMID: 32839399 DOI: 10.3390/pathogens9090685] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Zaffiri L, Frankel C, Bush EJ, Neely ML, Pavlisko EN, Mokrova IL, Luftig MA, Palmer SM. Evidence of Epstein-Barr virus heterogeneous gene expression in adult lung transplant recipients with posttransplant lymphoproliferative disorder. J Med Virol 2021;93:5040-7. [PMID: 33704812 DOI: 10.1002/jmv.26936] [Reference Citation Analysis]
17 Heuts F, Rottenberg ME, Salamon D, Rasul E, Adori M, Klein G, Klein E, Nagy N. T cells modulate Epstein-Barr virus latency phenotypes during infection of humanized mice. J Virol 2014;88:3235-45. [PMID: 24390326 DOI: 10.1128/JVI.02885-13] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
18 Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Hervé Fridman W, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: DNA vaccines for cancer therapy. Oncoimmunology 2014;3:e28185. [PMID: 24800178 DOI: 10.4161/onci.28185] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
19 Kurucz I, Peter B, Prosz A, Szekacs I, Horvath R, Erdei A. Label-free optical biosensor for on-line monitoring the integrated response of human B cells upon the engagement of stimulatory and inhibitory immune receptors. Sensors and Actuators B: Chemical 2017;240:528-35. [DOI: 10.1016/j.snb.2016.09.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
20 Xia TL, Li X, Wang X, Zhu YJ, Zhang H, Cheng W, Chen ML, Ye Y, Li Y, Zhang A, Dai DL, Zhu QY, Yuan L, Zheng J, Huang H, Chen SQ, Xiao ZW, Wang HB, Roy G, Zhong Q, Lin D, Zeng YX, Wang J, Zhao B, Gewurz BE, Chen J, Zuo Z, Zeng MS. N(6)-methyladenosine-binding protein YTHDF1 suppresses EBV replication and promotes EBV RNA decay. EMBO Rep 2021;22:e50128. [PMID: 33605073 DOI: 10.15252/embr.202050128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]